Cell death modalities act to clear unwanted cells, but disproportionate responses can contribute to the detrimental loss of kidney cells
External resources New England Journal of Medicine: Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) JAMA: SURMOUNT-4 Continued Treatment With Tirzepatide for Maintenance of Weight Reduction JCI Insight: Tirzepatide Is an Imbalanced and Biased Dual GIP and GLP-1 Receptor Agonist For researchers serious about optimizing their tirzepatide protocol, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, proven protocols, and a community of thousands who have navigated these exact questions
In our study in rheumatoid arthritis, we saw that nearly one-third of patients actually discontinued therapy within a year, and most commonly that was due to gastrointestinal or GI symptoms
Most amino acids can activate mTORC1 and, in turn, are regulated by the mTORC1 signaling pathway
If you are unsure what to do after a missed dose, contact the pharmacy team before making changes yourself